In silico drug repurposing of anticancer drug 5-FU and analogues against SARS-CoV-2 main protease
The pressing need to find effective drugs against the current deadly COVID-19 disease has recently motivated numerous studies using different approaches to address the problem. One time-saving and less costly strategy is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same trend, this study has investigated the potential inhibitory activity of 5-FU and its analogues against the SARS-CoV-2 main protease as well as their profile of druggability using molecular docking and ADMET methods. From the calculations performed, four candidates showed promising results with respect to the binding affinity to the target protease, 3CLpro, the therapeutic profile of druggability and safety. Further in-vitro and in-vivo investigations are needed that may clarify their possible mechanism of the pharmacological action to combat COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
chemRxiv.org - (2021) vom: 28. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matondo, Aristote [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.26434/chemrxiv-2021-gk1gt |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XCH036682020 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XCH036682020 | ||
| 003 | DE-627 | ||
| 005 | 20230429143413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220728s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26434/chemrxiv-2021-gk1gt |2 doi | |
| 035 | |a (DE-627)XCH036682020 | ||
| 035 | |a (chemrXiv)10.26434/chemrxiv-2021-gk1gt | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matondo, Aristote |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In silico drug repurposing of anticancer drug 5-FU and analogues against SARS-CoV-2 main protease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The pressing need to find effective drugs against the current deadly COVID-19 disease has recently motivated numerous studies using different approaches to address the problem. One time-saving and less costly strategy is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same trend, this study has investigated the potential inhibitory activity of 5-FU and its analogues against the SARS-CoV-2 main protease as well as their profile of druggability using molecular docking and ADMET methods. From the calculations performed, four candidates showed promising results with respect to the binding affinity to the target protease, 3CLpro, the therapeutic profile of druggability and safety. Further in-vitro and in-vivo investigations are needed that may clarify their possible mechanism of the pharmacological action to combat COVID-19. | ||
| 650 | 4 | |a Chemistry |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 540 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Dendera, Washington |e verfasserin |4 aut | |
| 700 | 1 | |a Isamura, Bienfait K. |e verfasserin |4 aut | |
| 700 | 1 | |a Ngbolua, Koto-te-Nyiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Mambo, Hilaire V.S. |e verfasserin |4 aut | |
| 700 | 1 | |a Muzomwe, Mayaliwa |e verfasserin |4 aut | |
| 700 | 1 | |a Mudogo, Virima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t chemRxiv.org |g (2021) vom: 28. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26434/chemrxiv-2021-gk1gt |z kostenfrei |3 Volltext |
| 912 | |a GBV_XCH | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 28 |c 12 | ||